Navigation Links
Epilepsy Drug May Relieve Chronic Headaches

Researchers say the drug gabapentin (Neurontin) taken at 2,400 milligrams a day is an effective preventive measure // for people with chronic daily headaches.
Gabapentin is an approved anti-epileptic drug. Studies have also shown its success in treating other pain-related health issues like diabetic neuropathy, postherpetic neuralgia, and migraine headache. Since gabapentin often reduces migraines by more than 50 percent and chronic daily headaches often have migraine-like features, researchers in Australia conducted a double-blind, placebo-controlled study to determine the drug's specific effect on chronic daily headaches. This type of study is the gold standard of clinical research studies where neither the researchers nor the participants know who received the drug or an identical dummy substance, called a placebo.

For the study researchers recruited 133 patients who had headaches at least 15 days every month that lasted more than four hours at a time. The patients were randomly selected to receive gabapentin or a placebo for six weeks. After that period, none of the patients received either treatment for a week, and then each group switched to the opposite treatment for a second six weeks.

Results showed 36 percent of the patients taking 2,400 milligrams of gabapentin a day stopped having chronic daily headaches. Negative effects of the drug included vomiting, dizziness, dysarthria (problems speaking), sleepiness, and constipation.
'"/>




Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drugs Can Enhance Risk of Birth Defects
5. Epilepsy Drug Helps Diabetic Nerve Damage
6. More Complications Seen In Women With Epilepsy
7. Epilepsy Drugs Found To Lead To Bone Loss
8. Another Use For Epilepsy Drugs
9. Epilepsy Patients Could Benefit From Pacemakers
10. Early Surgery For Treatment Of Epilepsy Questioned
11. Epilepsy Drug Valproate and Lamotrigine Linked To Malformed Fetus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: